Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PAHC
PAHC logo

PAHC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
57.600
Open
55.920
VWAP
55.60
Vol
377.37K
Mkt Cap
2.22B
Low
54.440
Amount
20.98M
EV/EBITDA(TTM)
12.19
Total Shares
40.53M
EV
2.90B
EV/OCF(TTM)
31.14
P/S(TTM)
1.54
Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. It has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.
Show More

Events Timeline

(ET)
2026-02-04
16:30:00
Raises FY26 Revenue Outlook to $1.45B
select
2026-02-04
16:30:00
Company Reports Q2 Revenue of $373.9M, Exceeding Expectations
select
2025-12-18 (ET)
2025-12-18
16:20:00
Phibro Animal Health Corporation Leadership Transition Supports Long-Term Growth
select
2025-11-05 (ET)
2025-11-05
18:06:42
Phibro Animal Health projects FY26 EPS between $2.64 and $2.81, in line with consensus of $2.63
select
2025-11-05
18:05:52
Phibro Animal Health Announces Q1 EPS of 73c, Exceeding Consensus Estimate of 60c
select
2025-10-30 (ET)
2025-10-30
13:02:17
Phibro Animal Health Unveils Nationwide Release of Restoris Dental Gel
select
2025-10-09 (ET)
2025-10-09
16:31:10
Phibro Animal Health Signs Licensing Agreement with Lighthouse Pharmaceuticals
select

News

NASDAQ.COM
7.5
03-24NASDAQ.COM
Omnicell Advances Vision of Autonomous Pharmacy Amid Challenges
  • Vision for Autonomous Pharmacy: Omnicell is committed to advancing the industry-defined vision of the autonomous pharmacy, aiming for zero-error medication management by enhancing operational efficiencies, having expanded from a single-point solution to a diversified product platform over recent years, thereby strengthening its market competitiveness.
  • Expansion of SaaS and Expert Services: The company is steadily increasing revenue from its SaaS and Expert Services through acquisitions and new platform launches, with several health systems committing to its inventory optimization service in Q4 2025, indicating robust market demand.
  • Strong Financial Health: As of Q4 2025, Omnicell reported cash and cash equivalents of $197 million against total debt of $168 million, reflecting a solid solvency position with a debt-to-capital ratio reduced to 12.1%, which supports future investments and expansion.
  • Cost Pressures Impacting Margins: Despite successes in various sectors, Omnicell faced challenges from labor shortages and rising raw material costs, leading to a year-over-year decline of approximately 4 percentage points in non-GAAP gross margin in Q4 2025, which may strain profit margins.
moomoo
5.0
03-13moomoo
Form 144: Phibro Animal Health (PAHC.US) 10% Stakeholder Plans to Sell $12.19 Million in Common Shares
  • Stock Sale Announcement: BFI Co. LLC plans to sell 246.4K shares of its common stock in Phibro Animal Health (PAHC.US), valued at approximately $12.19 million.

  • Reduction in Shareholding: BFI Co. LLC has decreased its shareholding in Phibro Animal Health by 302.72K shares since January 7, 2026, with a total value of around $14.54 million.

Fool
5.0
02-27Fool
Phibro Animal Health CEO Executes Share Sale Amid Strong Performance
  • Executive Share Sale: Jack Bendheim, CEO of Phibro Animal Health Corporation, sold 14,080 shares of common stock through indirect open-market transactions on February 13 and 18, 2026, for total proceeds of approximately $728,000, indicating proactive management of executive holdings.
  • Ownership Analysis: Post-transaction, Bendheim retains 16,840 shares directly and 36,680 shares indirectly, totaling 53,520 shares, suggesting a continued optimistic outlook on the company's future without an immediate rush to liquidate his holdings.
  • Transaction Context: This sale was executed under a Rule 10b5-1 trading plan adopted in May 2025, aimed at avoiding insider trading allegations, highlighting the executive's commitment to transparency and compliance.
  • Company Performance Highlights: Phibro reported a 21% year-over-year revenue increase in its fiscal Q2 2026, reaching $373.9 million, and raised its full-year revenue guidance to between $1.45 billion and $1.50 billion, reflecting strong performance in the animal health sector.
Yahoo Finance
5.0
02-27Yahoo Finance
Jack Bendheim's Executive Update
  • Executive Leadership Update: Jack Bendheim continues to serve as the company's Director, President, and CEO as of February 24, 2026, holding a 10% ownership stake, reflecting his ongoing commitment and leadership.
  • Governance Stability: Bendheim's continued role helps maintain governance stability, ensuring consistency in strategic direction, which in turn enhances investor confidence.
  • Market Reaction Expectations: While specific financial data is not disclosed, Bendheim's leadership experience may positively impact the company's future market performance, especially in uncertain economic conditions.
  • Strategic Development Potential: Under Bendheim's leadership, the company is poised to achieve strategic development goals, further enhancing its market competitiveness and business growth potential.
Fool
5.0
02-22Fool
Phibro Animal Health CEO Sells 72,198 Shares in Open Market
  • Executive Sale Overview: Jack Bendheim, CEO of Phibro Animal Health, sold 72,198 shares in multiple open-market transactions between February 10 and 11, 2026, totaling approximately $3.74 million, indicating sustained confidence in the company's stock despite the sale.
  • Ownership Impact: The transaction resulted in approximately 51.64% of Bendheim's total holdings (both direct and indirect) being disposed of, with the indirect account (BFI Co. LLC) experiencing a significant 58.72% reduction, reflecting the executive's sensitivity to market dynamics.
  • Transaction Context: This sale was executed under a pre-existing Rule 10b5-1 trading plan at a weighted average price of around $51.77 per share, indicating a strategic approach to risk management amidst market fluctuations.
  • Company Performance Outlook: Phibro's Q2 fiscal year 2026 earnings report showed year-over-year growth in revenue, net income, and earnings per share, with the CEO expressing confidence in future performance, particularly in the demand for its nutrition products and vaccines, which are expected to drive long-term growth.
Yahoo Finance
5.0
02-22Yahoo Finance
Phibro Animal Health CEO Sells 72,198 Shares After Strong Q2 2026 Performance
  • Transaction Overview: Jack Bendheim, CEO of Phibro Animal Health, sold 72,198 shares in multiple open-market transactions between February 10 and 11, 2026, totaling approximately $3.74 million, indicating confidence in the company's future prospects.
  • Ownership Impact: This transaction resulted in approximately 51.64% of Bendheim's total holdings being disposed of, with the indirect account (BFI Co. LLC) experiencing a significant 58.72% reduction, reflecting sensitivity to market dynamics.
  • Trading Plan Context: The sale was executed under a pre-existing Rule 10b5-1 trading plan at a weighted average price of around $51.77 per share, indicating that Bendheim's actions were not influenced by recent company news, thus maintaining transparency.
  • Company Performance Highlights: Phibro reported year-over-year revenue growth in its Q2 2026 earnings, with net income reaching $92.09 million, underscoring strong demand for its animal nutrition products and vaccines, suggesting promising future growth potential.
Wall Street analysts forecast PAHC stock price to rise
2 Analyst Rating
Wall Street analysts forecast PAHC stock price to rise
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
45.00
Averages
47.50
High
50.00
Current: 0.000
sliders
Low
45.00
Averages
47.50
High
50.00
Morgan Stanley
Equal Weight
maintain
$45 -> $49
AI Analysis
2026-02-06
Reason
Morgan Stanley
Price Target
$45 -> $49
AI Analysis
2026-02-06
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Phibro Animal Health to $49 from $45 and keeps an Equal Weight rating on the shares. Phibro's latest print reflects solid execution, particularly around its Zoetis MFA transaction/Animal Health segment/cost management, with a Q2 beat, raised FY26 guidance, and notable margin expansion, the analyst tells investors in a research note.
JPMorgan
NULL -> Overweight
upgrade
$45 -> $50
2025-11-07
Reason
JPMorgan
Price Target
$45 -> $50
2025-11-07
upgrade
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Phibro Animal Health to $50 from $45 and keeps an Overweight rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PAHC
Unlock Now

Valuation Metrics

The current forward P/E ratio for Phibro Animal Health Corp (PAHC.O) is 10.56, compared to its 5-year average forward P/E of 13.19. For a more detailed relative valuation and DCF analysis to assess Phibro Animal Health Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
13.19
Current PE
10.56
Overvalued PE
16.26
Undervalued PE
10.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
9.12
Current EV/EBITDA
12.56
Overvalued EV/EBITDA
10.73
Undervalued EV/EBITDA
7.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.78
Current PS
1.45
Overvalued PS
1.03
Undervalued PS
0.53

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

Stocks for short term gans
Intellectia · 19 candidates
Market Cap: >= 2.00BRsi Category: moderate, overboughtRelative Vol: >= 2Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $10.00
Ticker
Name
Market Cap$
top bottom
LBTYB logo
LBTYB
Liberty Global Ltd
6.07B
PAHC logo
PAHC
Phibro Animal Health Corp
2.15B
ALGT logo
ALGT
Allegiant Travel Co
2.10B
NVST logo
NVST
Envista Holdings Corp
4.77B
XPO logo
XPO
XPO Inc
23.85B
RRX logo
RRX
Regal Rexnord Corp
14.06B
what stocks will
Intellectia · 3459 candidates
Market Cap: >= 100.00MPrice: $1.00 - $200.00Monthly Average Dollar Volume: >= 100,000
Ticker
Name
Market Cap$
top bottom
KELYB logo
KELYB
Kelly Services Inc
510.65M
PSNY logo
PSNY
Polestar Automotive Holding UK PLC
1.21B
PAHC logo
PAHC
Phibro Animal Health Corp
1.66B
FORM logo
FORM
FormFactor Inc
5.43B
LBRX logo
LBRX
LB Pharmaceuticals Inc
526.22M
ENSG logo
ENSG
Ensign Group Inc
10.05B

Whales Holding PAHC

C
Castleknight Management LP
Holding
PAHC
+19.38%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Phibro Animal Health Corp (PAHC) stock price today?

The current price of PAHC is 54.76 USD — it has decreased -0.99

What is Phibro Animal Health Corp (PAHC)'s business?

Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. It has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

What is the price predicton of PAHC Stock?

Wall Street analysts forecast PAHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAHC is47.50 USD with a low forecast of 45.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Phibro Animal Health Corp (PAHC)'s revenue for the last quarter?

Phibro Animal Health Corp revenue for the last quarter amounts to 373.91M USD, increased 20.90

What is Phibro Animal Health Corp (PAHC)'s earnings per share (EPS) for the last quarter?

Phibro Animal Health Corp. EPS for the last quarter amounts to 0.67 USD, increased 737.50

How many employees does Phibro Animal Health Corp (PAHC). have?

Phibro Animal Health Corp (PAHC) has 2475 emplpoyees as of April 02 2026.

What is Phibro Animal Health Corp (PAHC) market cap?

Today PAHC has the market capitalization of 2.22B USD.